How have the shares performed?
Brooklyn ImmunoTherapeutics Inc. (BTX) saw an uptrend of 6.43% in the recent trading with $15.22 being its most recent. The current price level -81.13% lower than the highest price of $80.67 marked by the stock while trading over the past 52-weeks, whereas it is 661.00% higher than the lowest price of $2.00 the company dropped to over past 52-weeks. The latest news story on BTX appeared in GlobeNewswire under the title “Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics” on Jun-14-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -34.90% below one month high and is +14.26% above of the lowest during that time. Looking into the simple moving average, Brooklyn ImmunoTherapeutics Inc. (BTX)’s stock stands at a SMA-50 of $19.97 while that of 5-day is reading $14.95.
Brooklyn ImmunoTherapeutics Inc. Earnings – What Happened With BTX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. During the reported three-month period, company’s sales were $1.18 billion.
BTX – Brooklyn ImmunoTherapeutics Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 27.80 million. BTX does have institutional investors; and they hold 0.40% of the stock.
Brooklyn ImmunoTherapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares. On the other hand, BTX declared 21,340 shares have been sold in 10 insider transactions over the past three months.
As on Mar 30, 2021, Eagle Asset Management Inc was the top most holder in Brooklyn ImmunoTherapeutics Inc. (AMEX:BTX) with an ownership of 46826.0 shares of the company or 0.11% of the stake worth $0.17 million. The filing also reveals Citadel Advisors LLC as the second largest holder in the company with a control over 0.05% of the outstanding shares. Its stake is worth $84998.0 for having 22849.0 shares in hand.
Renaissance Technologies, LLC also came holding a key position in the company during the recent quarter and it now holds 0.05% of the outstanding shares. With this there are now 17 institutions which have possession in BTX’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. The count was 62.59 for long-term debt to equity ratio.